Evaluating Silk Road Medical: Insights From 6 Financial Analysts
Portfolio Pulse from Benzinga Insights
Silk Road Medical (NASDAQ:SILK) received mixed ratings from 6 analysts, with a shift towards a neutral stance in the last 30 days. The average 12-month price target was raised to $20.83, indicating a 33.53% increase from the previous target. The company, focusing on reducing stroke risks through its TCAR procedure, shows a revenue growth of 17.97% but struggles with profitability, having a net margin of -27.52%. Its financial strength is noted with an exceptional ROE of -8.55% and a conservative debt management with a debt-to-equity ratio of 0.51.
May 01, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silk Road Medical has seen a recent shift in analyst sentiment, with an updated average price target of $20.83, suggesting a positive outlook. The company's significant revenue growth and strong ROE, despite its profitability challenges, highlight its potential.
The increase in the average price target to $20.83 from $15.60, based on analyst ratings, suggests a bullish outlook for Silk Road Medical in the short term. The company's revenue growth of 17.97% and exceptional ROE of -8.55%, despite a net margin of -27.52%, indicate strong financial health and operational efficiency, which are likely to positively impact its stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100